All In Biotech

Drug Trial Radar · NCT00307437

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,230

Actual

Start

May 2005

Primary completion

Dec 2006

Study completion Oct 2011

Sponsor

Lead sponsor
Centocor Research & Development, Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • Placebo; Ustekinumab (CNTO 1275) 45 or 90 mgDrug

    Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264

  • Ustekinumab (CNTO 1275) 45 mgDrug

    Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264

  • Ustekinumab (CNTO 1275) 90 mgDrug

    Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12Time frame: Week 0 to Week 12

Locations

62 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Normal, Illinois

  • Site not named

    Skokie, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Andover, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Port Huron, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Plymouth Meeting, Pennsylvania

  • Site not named

    Mt. Pleasant, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Surrey, British Columbia, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Moncton, New Brunswick, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Barrie, Ontario, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    London, Ontario, Canada

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.